Adult soft tissue sarcomas: Conventional therapies and molecularly targeted approaches

Cancer Treatment Reviews

Volumn 32, Issue 1, 2006, Pages 9-27

  Mocellin, Simone ^a,b   Rossi, Carlo R ^a   Brandes, Alba ^a   Nitti, Donato ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Cancer vaccine; Chemotherapy; Gene therapy; Molecular therapy; Radiotherapy; Soft tissue sarcoma; Surgery; Targeted therapy

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; CANCER VACCINE; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; HYBRID PROTEIN; IFOSFAMIDE; IM 862; IMATINIB; INDINAVIR; MARIMASTAT; PORPHYRIN DERIVATIVE; PRINOMASTAT; SAQUINAVIR; SEMAXANIB; SORAFENIB; TRABECTEDIN; TRASTUZUMAB; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

CANCER CONTROL; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURGERY; CARCINOGENESIS; CLINICAL TRIAL; DRUG EFFICACY; GENE DELIVERY SYSTEM; GENE FUNCTION; GENE TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INOPERABLE CANCER; INTENSITY MODULATED RADIATION THERAPY; MEDICAL DECISION MAKING; METASTASIS; NONHUMAN; PHYSICIAN; PROGNOSIS; REVIEW; SIDE EFFECT; SOFT TISSUE SARCOMA; TREATMENT PLANNING;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CHEMOTHERAPY, ADJUVANT; ENZYME INHIBITORS; GENE THERAPY; GROWTH SUBSTANCES; HUMANS; MATRIX METALLOPROTEINASES; MIDDLE AGED; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; SARCOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 31544477155     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2005.10.003     Document Type: Review

References (234)

1. A. Jemal R.C. Tiwari T. Murray A. Ghafoor A. Samuels E. Ward et al. Cancer statistics, 2004 CA Cancer J Clin 54 2004 8-29
2. P.C. Hogendoorn Pathology of soft tissue sarcomas with emphasis on molecular diagnostic techniques Eur J Cancer 2003 S205-S210
3. J.N. Cormier R.E. Pollock Soft tissue sarcomas CA Cancer J Clin 54 2004 94-109
4. E.C. Borden L.H. Baker R.S. Bell V. Bramwell G.D. Demetri B.L. Eisenberg et al. Soft tissue sarcomas of adults: State of the translational science Clin Cancer Res 9 2003 1941-1956
5. M. Brennan K. Alektiar R. Maki Sarcomas of the soft tissue and bone V. De Vita S. Hellman S. Rosenberg Cancer: Principles and practice of oncology vol. 2 2001 Lippincott Williams and Wilkins Philadelphia 1841-1935
6. B. O'Sullivan P.W. Pisters Staging and prognostic factor evaluation in soft tissue sarcoma Surg Oncol Clin N Am 12 2003 333-353
7. L.J. Helman P. Meltzer Mechanisms of sarcoma development Nat Rev Cancer 3 2003 685-694
8. J.A. Fletcher Molecular biology and cytogenetics of soft tissue sarcomas: Relevance for targeted therapies Cancer Treat Res 120 2004 99-116
9. M.A. Clark J.M. Thomas Amputation for soft-tissue sarcoma Lancet Oncol 4 2003 335-342
10. S.A. Rosenberg J. Tepper E. Glatstein J. Costa A. Baker M. Brennan et al. The treatment of soft-tissue sarcomas of the extremities: Prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy Ann Surg 196 1982 305-315
11. M.F. Brennan E.S. Casper L.B. Harrison M.H. Shiu J. Gaynor S.I. Hajdu The role of multimodality therapy in soft-tissue sarcoma Ann Surg 214 1991 328-336
12. E. Tukiainen T. Bohling R. Huuhtanen Soft tissue sarcoma of the trunk and extremities Scand J Surg 92 2003 257-263
13. K.A. Siebenrock R. Hertel R. Ganz Unexpected resection of soft-tissue sarcoma. More mutilating surgery, higher local recurrence rates, and obscure prognosis as consequences of improper surgery Arch Orthop Trauma Surg 120 2000 65-69
14. G.K. Zagars M.T. Ballo P.W. Pisters R.E. Pollock S.R. Patel R.S. Benjamin Surgical margins and resection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy Cancer 97 2003 2544-2553
15. E.H. Baldini J. Goldberg C. Jenner J.B. Manola G.D. Demetri C.D. Fletcher et al. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk J Clin Oncol 17 1999 3252-3259
16. A. Stojadinovic D.H. Leung A. Hoos D.P. Jaques J.J. Lewis M.F. Brennan Analysis of the prognostic significance of microscopic margins in 2084 localized primary adult soft tissue sarcomas Ann Surg 235 2002 424-434
17. M.W. Kattan D.H. Leung M.F. Brennan Postoperative nomogram for 12-year sarcoma-specific death J Clin Oncol 20 2002 791-796
18. M.D. McKee D.F. Liu J.J. Brooks J.F. Gibbs D.L. Driscoll W.G. Kraybill The prognostic significance of margin width for extremity and trunk sarcoma J Surg Oncol 85 2004 68-76
19. N. Kawaguchi A.R. Ahmed S. Matsumoto J. Manabe Y. Matsushita The concept of curative margin in surgery for bone and soft tissue sarcoma Clin Orthop 2004 165-172
20. F. Willeke J.W. Sturm Minimal residual disease in soft-tissue sarcomas Semin Surg Oncol 20 2001 294-303
21. J. Nakasone T. Shimizu H. Gomyo Y. Yoshimura S. Wakabayashi K. et al. Mukaiyama Assessment of microinvasion with reverse transcriptase polymerase chain reaction in a case of synovial sarcoma J Orthop Sci 9 2004 162-165
22. Consensus Conference. Limb-sparing treatment of adult soft-tissue sarcomas and osteosarcomas. JAMA 1985;254:1791-4.
23. P.P. Lin V.B. Guzel P.W. Pisters G.K. Zagars K.L. Weber B.W. Feig et al. Surgical management of soft tissue sarcomas of the hand and foot Cancer 95 2002 852-861
24. P.W. Pisters D.H. Leung J. Woodruff W. Shi M.F. Brennan Analysis of prognostic factors in 1041 patients with localized soft tissue sarcomas of the extremities J Clin Oncol 14 1996 1679-1689
25. C.H. Gerrand J.S. Wunder R.A. Kandel B. O'Sullivan C.N. Catton R.S. Bell et al. Classification of positive margins after resection of soft-tissue sarcoma of the limb predicts the risk of local recurrence J Bone Joint Surg Br 83 2001 1149-1155
26. J.B. Fleming R.S. Berman S.C. Cheng N.P. Chen K.K. Hunt B.W. Feig et al. Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas J Clin Oncol 17 1999 2772-2780
27. C.R. Rossi M. Foletto S. Alessio N. Menin E. D'Amore A. et al. Rigon Limb-sparing treatment for soft tissue sarcomas: Influence of prognostic factors J Surg Oncol 63 1996 3-8
28. A. Stojadinovic D.P. Jaques D.H. Leung J.H. Healey M.F. Brennan Amputation for recurrent soft tissue sarcoma of the extremity: indications and outcome Ann Surg Oncol 8 2001 509-518
29. F.C. Eilber G. Rosen S.D. Nelson M. Selch F. Dorey J. Eckardt et al. High-grade extremity soft tissue sarcomas: Factors predictive of local recurrence and its effect on morbidity and mortality Ann Surg 237 2003 218-226
30. P.W. Pisters L.B. Harrison D.H. Leung J.M. Woodruff E.S. Casper M.F. Brennan Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma J Clin Oncol 14 1996 859-868
31. J.C. Yang A.E. Chang A.R. Baker W.F. Sindelar D.N. Danforth S.L. Topalian et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity J Clin Oncol 16 1998 197-203
32. V.K. Sondak J.M. Robertson J.J. Sussman P.A. Saran A.E. Chang T.S. Lawrence Preoperative idoxuridine and radiation for large soft tissue sarcomas: Clinical results with five-year follow-up Ann Surg Oncol 5 1998 106-112
33. G.K. Zagars M.T. Ballo P.W. Pisters R.E. Pollock S.R. Patel R.S. Benjamin et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: An analysis of 225 patients Cancer 97 2003 2530-2543
34. K.M. Alektiar D. Leung M.J. Zelefsky J.H. Healey M.F. Brennan Adjuvant brachytherapy for primary high-grade soft tissue sarcoma of the extremity Ann Surg Oncol 9 2002 48-56
35. H. Strander I. Turesson E. Cavallin-Stahl A systematic overview of radiation therapy effects in soft tissue sarcomas Acta Oncol 42 2003 516-531
36. K.M. Alektiar J. Velasco M.J. Zelefsky J.M. Woodruff J.J. Lewis M.F. Brennan Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of the extremity Int J Radiat Oncol Biol Phys 48 2000 1051-1058
37. K. Khanfir L. Alzieu P. Terrier C. Le Pechoux S. Bonvalot D. Vanel et al. Does adjuvant radiation therapy increase loco-regional control after optimal resection of soft-tissue sarcoma of the extremities Eur J Cancer 39 2003 1872-1880
38. J.M. Coindre P. Terrier N.B. Bui F. Bonichon F. Collin V. Le Doussal et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group J Clin Oncol 14 1996 869-877
39. R.J. Geer J. Woodruff E.S. Casper M.F. Brennan Management of small soft-tissue sarcoma of the extremity in adults Arch Surg 127 1992 1285-1289
40. C.P. Karakousis G.C. Zografos Radiation therapy for high grade soft tissue sarcomas of the extremities treated with limb-preserving surgery Eur J Surg Oncol 28 2002 431-436
41. B. O'Sullivan I. Ward C. Catton Recent advances in radiotherapy for soft-tissue sarcoma Curr Oncol Rep 5 2003 274-281
42. A. Pollack G.K. Zagars M.S. Goswitz R.A. Pollock B.W. Feig P.W. Pisters Preoperative vs. postoperative radiotherapy in the treatment of soft tissue sarcomas: A matter of presentation Int J Radiat Oncol Biol Phys 42 1998 563-572
43. B. O'Sullivan A.M. Davis R. Turcotte R. Bell C. Catton P. Chabot et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomised trial Lancet 359 2002 2235-2241
44. M.D. McCarter D.P. Jaques M.F. Brennan Randomized clinical trials in soft tissue sarcoma Surg Oncol Clin N Am 11 2002 11-22
45. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: Meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997;350:1647-54.
46. S. Frustaci F. Gherlinzoni A. De Paoli M. Bonetti A. Azzarelli A. Comandone et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: Results of the Italian randomized cooperative trial J Clin Oncol 19 2001 1238-1247
47. J.N. Cormier X. Huang Y. Xing P.F. Thall X. Wang R.S. Benjamin et al. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: Chemotherapy-associated outcomes J Clin Oncol 22 2004 4567-4574
48. V.H. Bramwell Adjuvant chemotherapy for adult soft tissue sarcoma: Is there a standard of care? J Clin Oncol 19 2001 1235-1237
49. F. Meric M. Milas K.K. Hunt K.R. Hess P.W. Pisters G. Hildebrandt et al. Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas J Clin Oncol 18 2000 3378-3383
50. P.W. Pisters S.R. Patel D.G. Varma S.C. Cheng N.P. Chen H.T. Nguyen et al. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: Long-term results from a single institution J Clin Oncol 15 1997 3481-3487
51. S.R. Grobmyer R.G. Maki G.D. Demetri M. Mazumdar E. Riedel M.F. Brennan et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma Ann Oncol 15 2004 1667-1672
52. E. Gortzak A. Azzarelli J. Buesa V.H. Bramwell F. van Coevorden A.N. van et al. Geel A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma Eur J Cancer 37 2001 1096-1103
53. F.C. Eilber G. Rosen J. Eckardt C. Forscher S.D. Nelson M. Selch et al. Treatment-induced pathologic necrosis: A predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas J Clin Oncol 19 2001 3203-3209
54. F. Meric K.R. Hess D.G. Varma K.K. Hunt P.W. Pisters K.M. Milas et al. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas Cancer 95 2002 1120-1126
55. P.W. Pisters M.T. Ballo S.R. Patel Preoperative chemoradiation treatment strategies for localized sarcoma Ann Surg Oncol 9 2002 535-542
56. H.J. Wanebo W.J. Temple M.B. Popp W. Constable B. Aron S.L. Cunningham Preoperative regional therapy for extremity sarcoma. A tricenter update Cancer 75 1995 2299-2306
57. E.A. Levine M. Trippon T.K. Das Gupta Preoperative multimodality treatment for soft tissue sarcomas Cancer 71 1993 3685-3689
58. J.H. Edmonson I.A. Petersen T.C. Shives M.R. Mahoney M.G. Rock M.G. Haddock et al. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: Initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor Cancer 94 2002 786-792
59. T.F. DeLaney I.J. Spiro H.D. Suit M.C. Gebhardt F.J. Hornicek H.J. Mankin et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas Int J Radiat Oncol Biol Phys 56 2003 1117-1127
60. P.W. Pisters M.T. Ballo M.J. Fenstermacher B.W. Feig K.K. Hunt K.A. Raymond et al. Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma J Clin Oncol 21 2003 3092-3097
61. R.M. Henshaw D.A. Priebat D.J. Perry B.M. Shmookler M.M. Malawer Survival after induction chemotherapy and surgical resection for high-grade soft tissue sarcoma. Is radiation necessary? Ann Surg Oncol 8 2001 484-495
62. A.M. Eggermont J.H. de Wilt T.L. ten Hagen Current uses of isolated limb perfusion in the clinic and a model system for new strategies Lancet Oncol 4 2003 429-437
63. C.R. Rossi S. Mocellin P. Pilati M. Foletto D. Nitti M. Lise TNFalpha-based isolated perfusion for limb-threatening soft tissue sarcomas: State of the art and future trends J Immunother 26 2003 291-300
64. S. Mocellin C.R. Rossi P. Pilati D. Nitti Tumor necrosis factor, cancer and anticancer therapy Cytokine Growth Factor Rev 16 2005 35-53
65. A.M. Eggermont H. Schraffordt Koops J.M. Klausner B.B. Kroon P.M. Schlag D. Lienard et al. Isolated limb perfusion with tumour necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience Ann Surg 224 1996 756-764
66. C.R. Rossi S. Mocellin P. Pilati M. Foletto L. Campana L. Quintieri et al. Hyperthermic isolated perfusion with low-dose tumor necrosis factor α and doxorubicin for the treatment of limb-threatening soft tissue sarcomas Ann Surg Oncol 12 5 2005 398-405
67. B.E. Plaat W.M. Molenaar M.F. Mastik J. Koudstaal E. van den Berg H.S. Koops et al. Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: Treatment response and clinical outcome related to changes in proliferation and apoptosis Clin Cancer Res 5 1999 1650-1657
68. F.J. Lejeune N. Pujol D. Lienard F. Mosimann W. Raffoul A. Genton et al. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities Eur J Surg Oncol 26 2000 669-678
69. E.M. Noorda B.C. Vrouenraets O.E. Nieweg F. van Coevorden G.W. van Slooten B.B. Kroon Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities Cancer 98 2003 1483-1490
70. D. Casara D. Rubello P. Pilati R. Scalerta M. Foletto C.R. Rossi Optimized procedure of real-time systemic leakage monitoring during isolated limb perfusion using a hand held gamma probe and 99mTc-HSA Nucl Med Commun 25 2004 61-66
71. E.M. Noorda B.C. Vrouenraets O.E. Nieweg F. Van Coevorden B.B. Kroon Isolated limb perfusion: What is the evidence for its use? Ann Surg Oncol 11 2004 837-845
72. J.J. Lewis D. Leung J.M. Woodruff M.F. Brennan Retroperitoneal soft-tissue sarcoma: Analysis of 500 patients treated and followed at a single institution Ann Surg 228 1998 355-365
73. E. Stoeckle J.M. Coindre S. Bonvalot G. Kantor P. Terrier F. Bonichon et al. Prognostic factors in retroperitoneal sarcoma: A multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group Cancer 92 2001 359-368
74. E. Youssef J. Fontanesi M. Mott M. Kraut D. Lucas H. Mekhael et al. Long-term outcome of combined modality therapy in retroperitoneal and deep-trunk soft-tissue sarcoma: Analysis of prognostic factors Int J Radiat Oncol Biol Phys 54 2002 514-519
75. I. Hassan S.Z. Park J.H. Donohue D.M. Nagorney P.A. Kay A.G. et al. Nasciemento Operative management of primary retroperitoneal sarcomas: A reappraisal of an institutional experience Ann Surg 239 2004 244-250
76. A. Gronchi P.G. Casali M. Fiore L. Mariani S. Lo Vullo R. Bertulli et al. Retroperitoneal soft tissue sarcomas: Patterns of recurrence in 167 patients treated at a single institution Cancer 100 2004 2448-2455
77. P.W. Pisters B. O'Sullivan Retroperitoneal sarcomas: Combined modality treatment approaches Curr Opin Oncol 14 2002 400-405
78. A. Pirayesh Y. Chee T. Helliwell M. Hershman S. Leinster M. Fordham et al. The management of retroperitoneal soft tissue sarcoma: A single institution experience with a review of the literature Eur J Surg Oncol 27 2001 491-497
79. L. Gilbeau G. Kantor E. Stoeckle P. Lagarde L. Thomas M. Kind et al. Surgical resection and radiotherapy for primary retroperitoneal soft tissue sarcoma Radiother Oncol 65 2002 137-143
80. J. Jones C. Catton B. O'Sullivan J. Couture R. Heisler R. Kandel et al. Initial results of a trial of preoperative external beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma Ann Surg Oncol 9 2002 346-354
81. S. Webb Advances in three-dimensional conformal radiation therapy physics with intensity modulation Lancet Oncol 1 2000 30-36
82. C.M. Wendtner S. Abdel-Rahman M. Krych J. Baumert L.H. Lindner A. Baur et al. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas J Clin Oncol 20 2002 3156-3164
83. I. Petersen M. Haddock J. Donohue D. Nagorney J. Grill D. Sargent et al. Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas Int J Radiat Oncol Biol Phys 52 2002 469-475
84. J.Y. Bobin T. Al-Lawati L.E. Granero M. Adham P. Romestaing O. Chapet et al. Surgical management of retroperitoneal sarcomas associated with external and intraoperative electron beam radiotherapy Eur J Surg Oncol 29 2003 676-681
85. K.M. Alektiar K. Hu L. Anderson M.F. Brennan L.B. Harrison High-dose-rate intraoperative radiation therapy (HDR-IORT) for retroperitoneal sarcomas Int J Radiat Oncol Biol Phys 47 2000 157-163
86. H.L. Gieschen I.J. Spiro H.D. Suit M.J. Ott D.W. Rattner M. Ancukiewicz et al. Long-term results of intraoperative electron beam radiotherapy for primary and recurrent retroperitoneal soft tissue sarcoma Int J Radiat Oncol Biol Phys 50 2001 127-131
87. W.F. Sindelar T.J. Kinsella P.W. Chen T.F. DeLaney J.E. Tepper S.A. et al. Rosenberg Intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized, clinical trial Arch Surg 128 1993 402-410
88. V.J. Verwaal S. van Ruth E. de Bree G.W. van Sloothen H. van Tinteren H. Boot et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer J Clin Oncol 21 2003 3737-3743
89. P. Pilati S. Mocellin C. Rossi M. Foletto L. Campana D. Nitti et al. Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma Ann Surg Oncol 10 2003 508-513
90. C. Rossi M. Foletto S. Mocellin P. Pilati M. De Simone M. Deraco et al. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis Cancer 94 2002 492-499
91. C.R. Rossi M. Deraco M. De Simone S. Mocellin P. Pilati M. Foletto et al. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients Cancer 100 2004 1943-1950
92. O. Glehen F. Mohamed F.N. Gilly Peritoneal carcinomatosis from digestive tract cancer: New management by cytoreductive surgery and intraperitoneal chemohyperthermia Lancet Oncol 5 2004 219-228
93. D.L. Bartlett J.F. Buell S.K. Libutti E. Reed K.B. Lee W.D. Figg et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumour necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis Cancer 83 1998 1251-1261
94. S.B. Brown E.A. Brown I. Walker The present and future role of photodynamic therapy in cancer treatment Lancet Oncol 5 2004 497-508
95. J.J. Wilson H. Jones M. Burock D. Smith D.L. Fraker J. Metz et al. Patterns of recurrence in patients treated with photodynamic therapy for intraperitoneal carcinomatosis and sarcomatosis Int J Oncol 24 2004 711-717
96. T.W. Bauer S.M. Hahn F.R. Spitz A. Kachur E. Glatstein D.L. Fraker Preliminary report of photodynamic therapy for intraperitoneal sarcomatosis Ann Surg Oncol 8 2001 254-259
97. S.K. Hendren S.M. Hahn F.R. Spitz T.W. Bauer S.C. Rubin T. Zhu et al. Phase II trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumours Ann Surg Oncol 8 2001 65-71
98. K.G. Billingsley J.J. Lewis D.H. Leung E.S. Casper J.M. Woodruff M.F. Brennan Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma Cancer 85 1999 389-395
99. G.K. Zagars M.T. Ballo P.W. Pisters R.E. Pollock S.R. Patel R.S. Benjamin Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: Analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy Int J Radiat Oncol Biol Phys 57 2003 739-747
100. A. Stojadinovic A. Yeh M.F. Brennan Completely resected recurrent soft tissue sarcoma: Primary anatomic site governs outcomes J Am Coll Surg 194 2002 436-447
101. M.R. Weiser R.J. Downey D.H. Leung M.F. Brennan Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma J Am Coll Surg 191 2000 184-190
102. E.K. Abdalla P.W. Pisters Metastasectomy for limited metastases from soft tissue sarcoma Curr Treat Options Oncol 3 2002 497-505
103. G.P. Midis R.E. Pollock N.P. Chen B.W. Feig A. Murphy A. Pollack et al. Locally recurrent soft tissue sarcoma of the extremities Surgery 123 1998 666-671
104. C. Catton A. Davis R. Bell B. O'Sullivan V. Fornasier J. Wunder et al. Soft tissue sarcoma of the extremity. Limb salvage after failure of combined conservative therapy Radiother Oncol 41 1996 209-214
105. P. Popov E. Tukiainen S. Asko-Seljavaara R. Huuhtanen M. Virolainen P. Virkkunen et al. Soft-tissue sarcomas of the upper extremity: Surgical treatment and outcome Plast Reconstr Surg 113 2004 222-230
106. L.K. Temple M.F. Brennan The role of pulmonary metastasectomy in soft tissue sarcoma Semin Thorac Cardiovasc Surg 14 2002 35-44
107. J.Y. Blay M. van Glabbeke J. Verweij A.T. van Oosterom A. Le Cesne J.W. Oosterhuis et al. Advanced soft-tissue sarcoma: A disease that is potentially curable for a subset of patients treated with chemotherapy Eur J Cancer 39 2003 64-69
108. R.S. Benjamin J. Rouesse H. Bourgeois Q.G. van Hoesel Should patients with advanced sarcomas be treated with chemotherapy? Eur J Cancer 34 1998 958-965
109. A.I. Spira D.S. Ettinger The use of chemotherapy in soft-tissue sarcomas Oncologist 7 2002 348-359
110. M. Van Glabbeke A.T. van Oosterom J.W. Oosterhuis H. Mouridsen D. Crowther R. Somers et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2185 patients treated with anthracycline-containing first-line regimens - a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study J Clin Oncol 17 1999 150-157
111. Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003:CD003293.
112. A.J. Spillane R. A'Hern I.R. Judson C. Fisher J.M. Thomas Synovial sarcoma: A clinicopathologic, staging, and prognostic assessment J Clin Oncol 18 2000 3794-3803
113. E.L. Spurrell C. Fisher J.M. Thomas I.R. Judson Prognostic factors in advanced synovial sarcoma: An analysis of 104 patients treated at the Royal Marsden Hospital Ann Oncol 2005
114. S.R. Patel S. Vadhan-Raj N. Papadopolous C. Plager M.A. Burgess C. Hays et al. High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies - dose-response and schedule dependence J Clin Oncol 15 1997 2378-2384
115. M. Lopez P. Vici L. Di Lauro S. Carpano Increasing single epirubicin doses in advanced soft tissue sarcomas J Clin Oncol 20 2002 1329-1334
116. F.P. Worden J.M. Taylor J.S. Biermann V.K. Sondak K.M. Leu R. Chugh et al. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma J Clin Oncol 23 2005 105-112
117. A. Le Cesne I. Judson D. Crowther S. Rodenhuis H.J. Keizer Q. Van Hoesel et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group J Clin Oncol 18 2000 2676-2684
118. A. Bertuzzi L. Castagna A. Nozza V. Quagliuolo L. Siracusano M. Balzarotti et al. High-dose chemotherapy in poor-prognosis adult small round-cell tumours: Clinical and molecular results from a prospective study J Clin Oncol 20 2002 2181-2188
119. M. Sawyer V. Bramwell The treatment of distant metastases in soft tissue sarcoma Semin Radiat Oncol 9 1999 389-400
120. J.Y. Blay D. Bouhour I. Ray-Coquard C. Dumontet T. Philip P. Biron High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults J Clin Oncol 18 2000 3643-3650
121. P. Reichardt High-dose chemotherapy in adult soft tissue sarcoma Crit Rev Oncol Hematol 41 2002 157-167
122. M.L. Hensley R. Maki E. Venkatraman G. Geller M. Lovegren C. Aghajanian et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial J Clin Oncol 20 2002 2824-2831
123. K.M. Leu L.J. Ostruszka D. Shewach M. Zalupski V. Sondak J.S. Biermann et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma J Clin Oncol 22 2004 1706-1712
124. W.J. Kostler T. Brodowicz Y. Attems M. Hejna S. Tomek G. Amann et al. Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: Results of a phase II trial Ann Oncol 12 2001 1281-1288
125. Z. Papai G. Bodoky J. Szanto I. Poller P. Rahoty S. Eckhardt et al. The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma Cancer 89 2000 177-180
126. A. Le Cesne J.Y. Blay I. Judson A. Van Oosterom J. Verweij J. Radford et al. Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial J Clin Oncol 23 2005 576-584
127. C.L. Mackall P.S. Meltzer L.J. Helman Focus on sarcomas Cancer Cell 2 2002 175-178
128. B.E. Plaat H. Hollema W.M. Molenaar G.H. Torn Broers J. Pijpe M.F. Mastik et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumours: Differences in clinical outcome and expression of multidrug resistance proteins J Clin Oncol 18 2000 3211-3220
129. C.R. Rossi S. Mocellin R. Mencarelli M. Foletto P. Pilati D. Nitti et al. Gastrointestinal stromal tumours: From a surgical to a molecular approach Int J Cancer 107 2003 171-176
130. H. Joensuu C. Fletcher S. Dimitrijevic S. Silberman P. Roberts G. Demetri Management of malignant gastrointestinal stromal tumours Lancet Oncol 3 2002 655-664
131. R.P. DeMatteo J.J. Lewis D. Leung S.S. Mudan J.M. Woodruff M.F. Brennan Two hundred gastrointestinal stromal tumours: Recurrence patterns and prognostic factors for survival Ann Surg 231 2000 51-58
132. G.D. Demetri M. von Mehren C.D. Blanke A.D. Van den Abbeele B. Eisenberg P.J. Roberts et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours N Engl J Med 347 2002 472-480
133. B.J. Druker Imatinib as a paradigm of targeted therapies Adv Cancer Res 91 2004 1-30
134. J. Verweij P.G. Casali J. Zalcberg A. LeCesne P. Reichardt J.Y. Blay et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial Lancet 364 2004 1127-1134
135. G. McArthur Molecularly targeted treatment for dermatofibrosarcoma protuberans Semin Oncol 31 2004 30-36
136. I. Gonzalez E.J. Andreu A. Panizo S. Inoges A. Fontalba J.L. Fernandez-Luna et al. Imatinib inhibits proliferation of Ewing tumour cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis Clin Cancer Res 10 2004 751-761
137. K. Scotlandi M.C. Manara R. Strammiello L. Landuzzi S. Benini S. Perdichizzi et al. C-kit receptor expression in Ewing's sarcoma: Lack of prognostic value but therapeutic targeting opportunities in appropriate conditions J Clin Oncol 21 2003 1952-1960
138. L.L. Chen J.C. Trent E.F. Wu G.N. Fuller L. Ramdas W. Zhang et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumours Cancer Res 64 2004 5913-5919
139. M.W. Deininger B.J. Druker SR Circumventing imatinib resistance Cancer Cell 6 2004 108-110
140. Y. Cao Antiangiogenic cancer therapy Semin Cancer Biol 14 2004 139-145
141. J.V. Heymach Angiogenesis and antiangiogenic approaches to sarcomas Curr Opin Oncol 13 2001 261-269
142. A. Stopeck M. Sheldon M. Vahedian G. Cropp R. Gosalia A. Hannah Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies Clin Cancer Res 8 2002 2798-2805
143. B.C. Kuenen J. Tabernero J. Baselga F. Cavalli E. Pfanner P.F. Conte et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma Clin Cancer Res 9 2003 1648-1655
144. J.V. Heymach J. Desai J. Manola D.W. Davis D.J. McConkey D. Harmon et al. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas Clin Cancer Res 10 2004 5732-5740
145. J.C. Gutheil T.N. Campbell P.R. Pierce J.D. Watkins W.D. Huse D.J. Bodkin et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3 Clin Cancer Res 6 2000 3056-3061
146. S.R. Patel J. Jenkins N. Papadopolous M.A. Burgess C. Plager J. Gutterman et al. Pilot study of vitaxin - an angiogenesis inhibitor-in patients with advanced leiomyosarcomas Cancer 92 2001 1347-1348
147. A. Noy D.T. Scadden J. Lee B.J. Dezube D. Aboulafia A. Tulpule et al. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but highlights sustained, potent effect of highly active antiretroviral therapy: From the AIDS Malignancy Consortium and IM862 Study Team J Clin Oncol 2004
148. D.J. Hicklin L.M. Ellis Role of the vascular endothelial growth factor pathway in tumour growth and angiogenesis J Clin Oncol 2004
149. C. Chao T. Al-Saleem J.J. Brooks A. Rogatko W.G. Kraybill B. Eisenberg Vascular endothelial growth factor and soft tissue sarcomas: Tumour expression correlates with grade Ann Surg Oncol 8 2001 260-267
150. A. Potti A.K. Ganti K. Tendulkar K. Sholes S. Chitajallu M. Koch et al. Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma J Cancer Res Clin Oncol 130 2004 52-56
151. B. Fuchs C.Y. Inwards R. Janknecht Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma Clin Cancer Res 10 2004 1344-1353
152. S.M. Wilhelm C. Carter L. Tang D. Wilkie A. McNabola H. Rong et al. BAY 43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis Cancer Res 64 2004 7099-7109
153. J. Holash S. Davis N. Papadopoulos S.D. Croll L. Ho M. Russell et al. VEGF-Trap: A VEGF blocker with potent antitumour effects Proc Natl Acad Sci USA 99 2002 11393-11398
154. H.T. Tran G.R. Blumenschein Jr. C. Lu C.A. Meyers V. Papadimitrakopoulou F.V. Fossella et al. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumours Cancer Chemother Pharmacol 54 2004 308-314
155. T. Vogt C. Hafner K. Bross F. Bataille K.W. Jauch A. Berand et al. Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumours Cancer
156. A. Reichle K. Bross T. Vogt F. Bataille P. Wild A. Berand et al. Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma Cancer 101 2004 2247-2256
157. M. Hidalgo S.G. Eckhardt Development of matrix metalloproteinase inhibitors in cancer therapy J Natl Cancer Inst 93 2001 178-193
158. T. Saito Y. Oda A. Sakamoto S. Tamiya Y. Iwamoto M. Tsuneyoshi Matrix metalloproteinase-2 expression correlates with morphological and immunohistochemical epithelial characteristics in synovial sarcoma Histopathology 40 2002 279-285
159. J. Sanceau S. Truchet B. Bauvois Matrix metalloproteinase-9 silencing by RNA interference triggers the migratory-adhesive switch in Ewing's sarcoma cells J Biol Chem 278 2003 36537-36546
160. T. Sato L. Koike Y. Miyata M. Hirata Y. Mimaki Y. Sashida et al. Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix metalloproteinases-1 and -9 in human fibrosarcoma HT-1080 cells Cancer Res 62 2002 1025-1029
161. C.M. Overall C. Lopez-Otin Strategies for MMP inhibition in cancer: Innovations for the post-trial era Nat Rev Cancer 2 2002 657-672
162. A. Albini M. Morini F. D'Agostini N. Ferrari F. Campelli G. Arena et al. Inhibition of angiogenesis-driven Kaposi's sarcoma tumour growth in nude mice by oral N-acetylcysteine Cancer Res 61 2001 8171-8178
163. C. Bremer C.H. Tung R. Weissleder In vivo molecular target assessment of matrix metalloproteinase inhibition Nat Med 7 2001 743-748
164. S. Syed C. Takimoto M. Hidalgo J. Rizzo J.G. Kuhn L.A. Hammond et al. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumour properties Clin Cancer Res 10 2004 6512-6521
165. L. Pantanowitz B.J. Dezube G.S. Pinkus S.R. Tahan Histological characterization of regression in acquired immunodeficiency syndrome-related Kaposi's sarcoma J Cutan Pathol 31 2004 26-34
166. M.A. Rudek W.D. Figg V. Dyer W. Dahut M.L. Turner S.M. Steinberg et al. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer J Clin Oncol 19 2001 584-592
167. M. Cianfrocca T.P. Cooley J.Y. Lee M.A. Rudek D.T. Scadden L. Ratner et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: A phase I AIDS malignancy consortium study J Clin Oncol 20 2002 153-159
168. P. Monini C. Sgadari E. Toschi G. Barillari B. Ensoli Antitumour effects of antiretroviral therapy Nat Rev Cancer 4 2004 861-875
169. P.M. Harari Epidermal growth factor receptor inhibition strategies in oncology Endocr Relat Cancer 11 2004 689-708
170. D. Beech R.E. Pollock R. Tsan R. Radinsky Epidermal growth factor receptor and insulin-like growth factor-I receptor expression and function in human soft-tissue sarcoma cells Int J Oncol 12 1998 329-336
171. T.O. Nielsen F.D. Hsu J.X. O'Connell C.B. Gilks P.H. Sorensen S. Linn et al. Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumours of similar histology Am J Pathol 163 2003 1449-1456
172. B.F. El-Rayes P.M. LoRusso Targeting the epidermal growth factor receptor Br J Cancer 91 2004 418-424
173. S.V. Allander P.B. Illei Y. Chen C.R. Antonescu M. Bittner M. Ladanyi et al. Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation Am J Pathol 161 2002 1587-1595
174. G. Amir J. Issakov I. Meller E. Sucher A. Peyser I.J. Cohen et al. Expression of p53 gene product and cell proliferation marker Ki-67 in Ewing's sarcoma: Correlation with clinical outcome Hum Pathol 33 2002 170-174
175. H. Foster S. Knox A.K. Ganti B.J. Hebert M. Koch K. Tendulkar et al. HER-2/neu overexpression detected by immunohistochemistry in soft tissue sarcomas Am J Clin Oncol 26 2003 188-191
176. P.G. Nuciforo C. Pellegrini R. Fasani M. Maggioni G. Coggi A. Parafioriti et al. Molecular and immunohistochemical analysis of HER2/ neu oncogene in synovial sarcoma Hum Pathol 34 2003 639-645
177. T. Sato M. Peiper A. Heinecke D. Zurakowski C.F. Eisenberger S. Hosch et al. Expression of HER2/neu does not correlate with survival in soft tissue sarcoma Onkologie 26 2003 268-271
178. P. Nanni G. Nicoletti C. De Giovanni S. Croci A. Astolfi L. Landuzzi et al. Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice Cancer Res 63 2003 2728-2732
179. D. Ye A. Maitra C.F. Timmons P.J. Leavey R. Ashfaq R.L. Ilaria Jr. The epidermal growth factor receptor HER2 is not a major therapeutic target in Ewing sarcoma J Pediatr Hematol Oncol 25 2003 459-466
180. M.A. Bjornsti P.J. Houghton Lost in translation: Dysregulation of cap-dependent translation and cancer Cancer Cell 5 2004 519-523
181. E. Raymond J. Alexandre S. Faivre K. Vera E. Materman J. Boni et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer J Clin Oncol 22 2004 2336-2347
182. C.E. Thomas A. Ehrhardt M.A. Kay Progress and problems with the use of viral vectors for gene therapy Nat Rev Genet 4 2003 346-358
183. A. El-Aneed Current strategies in cancer gene therapy Eur J Pharmacol 498 2004 1-8
184. H. Kovar J. Ban S. Pospisilova Potentials for RNAi in sarcoma research and therapy: Ewing's sarcoma as a model Semin Cancer Biol 13 2003 275-281
185. M. Milas D. Yu A. Lang T. Ge B. Feig A.K. El-Naggar et al. Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumourigenicity Cancer Gene Ther 7 2000 422-429
186. M. Zhan D. Yu A. Lang L. Li R.E. Pollock Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression Cancer 92 2001 1556-1566
187. S. Fruehauf M.R. Veldwijk S. Berlinghoff N. Basara C. Baum M. et al. Flasshove Gene therapy for sarcoma Cells Tissue Organs 172 2002 133-144
188. K. Scotlandi C. Maini M.C. Manara S. Benini M. Serra V. Cerisano et al. Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells Cancer Gene Ther 9 2002 296-307
189. C. Thallinger M.F. Wolschek H. Maierhofer H. Skvara H. Pehamberger B.P. et al. Monia Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide Clin Cancer Res 10 2004 4185-4191
190. N. Shinomiya C.F. Gao Q. Xie M. Gustafson D.J. Waters Y.W. Zhang et al. RNA interference reveals that ligand-independent met activity is required for tumour cell signaling and survival Cancer Res 64 2004 7962-7970
191. P. Wurl M. Kappler A. Meye F. Bartel T. Kohler C. et al. Lautenschlager Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma Lancet 359 2002 943-945
192. M. Kappler M. Bache F. Bartel M. Kotzsch M. Panian P. Wurl et al. Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53 Cancer Gene Ther 11 2004 186-193
193. T.E. Lans T.L. Ten Hagen R. Van Horssen P.C. Wu S.T. Van Tiel S.K. et al. Libutti Improved antitumour response to isolated limb perfusion with tumour necrosis factor after upregulation of endothelial monocyte-activating polypeptide II in soft tissue sarcoma Ann Surg Oncol 9 2002 812-819
194. J.H. de Wilt A. Bout A.M. Eggermont S.T. van Tiel M.W. de Vries T.L. ten Hagen et al. Adenovirus-mediated interleukin 3 beta gene transfer by isolated limb perfusion inhibits growth of limb sarcoma in rats Hum Gene Ther 12 2001 489-502
195. L.M. Pasetto U. Basso A.A. Brandes Improved tolerability of chemotherapy in soft tissue sarcomas: Old and new strategies Expert Rev Anticancer Ther 3 2003 167-178
196. H.X. Chen J.L. Marshall E. Ness R.R. Martin B. Dvorchik N. Rizvi et al. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumours Clin Cancer Res 6 2000 1259-1266
197. E. Galanis E.M. Hersh A.T. Stopeck R. Gonzalez P. Burch C. Spier et al. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: Phase I/II experience J Clin Oncol 17 1999 3313-3323
198. S. Ries W.M. Korn ONYX-015: Mechanisms of action and clinical potential of a replication-selective adenovirus Br J Cancer 86 2002 5-11
199. E. Galanis S.H. Okuno A.G. Nascimento B.D. Lewis R.A. Lee A.M. et al. Oliveira Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas Gene Ther 2005
200. W. Lu S. Zheng X.F. Li J.J. Huang X. Zheng Z. Li Intra-tumour injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: A pilot phase II clinical trial World J Gastroenterol 10 2004 3634-3638
201. N. Senzer S. Mani A. Rosemurgy J. Nemunaitis C. Cunningham C. Guha et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumour necrosis factor alpha gene: A phase I study in patients with solid tumours J Clin Oncol 22 2004 592-601
202. A.J. Mundt S. Vijayakumar J. Nemunaitis A. Sandler H. Schwartz N. Hanna et al. A phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities Clin Cancer Res 10 2004 5747-5753
203. S.A. Rosenberg J.C. Yang N.P. Restifo Cancer immunotherapy: Moving beyond current vaccines Nat Med 10 2004 909-915
204. S. Mocellin C.R. Rossi D. Nitti Cancer vaccine development: On the way to break immune tolerance to malignant cells Exp Cell Res 299 2004 267-278
205. S. Mocellin S. Mandruzzato V. Bronte M. Lise D. Nitti Part I: Vaccines for solid tumours Lancet Oncol 5 2004 681-689
206. J. Stebbing M. Bower P. Srivastava Kaposi's sarcoma as a model for cancer immunotherapy Trends Mol Med 10 2004 187-193
207. R.G. Maki Immunity against soft-tissue sarcomas Curr Oncol Rep 5 2003 282-287
208. Y. Sato Y. Nabeta T. Tsukahara Y. Hirohashi R. Syunsui A. Maeda et al. Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma J Immunol 169 2002 1611-1618
209. B.S. Worley L.T. van den Broeke T.J. Goletz C.D. Pendleton E.M. Daschbach E.K. Thomas et al. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations Cancer Res 61 2001 6868-6875
210. B. Ludewig A.F. Ochsenbein B. Odermatt D. Paulin H. Hengartner R.M. Zinkernagel Immunotherapy with dendritic cells directed against tumour antigens shared with normal host cells results in severe autoimmune disease J Exp Med 191 2000 795-804
211. S. Mocellin G. Semenzato S. Mandruzzato C. Riccardo Rossi Part II: Vaccines for haematological malignant disorders Lancet Oncol 5 2004 727-737
212. P.M. Alves O. Faure S. Graff-Dubois D.A. Gross S. Cornet S. Chouaib et al. EphA2 as target of anticancer immunotherapy: Identification of HLA-A*0201-restricted epitopes Cancer Res 63 2003 8476-8480
213. S.Y. Lee Y. Obata M. Yoshida E. Stockert B. Williamson A.A. Jungbluth et al. Immunomic analysis of human sarcoma Proc Natl Acad Sci USA 100 2003 2651-2656
214. P. Dalerba E. Frascella B. Macino S. Mandruzzato A. Zambon A. Rosolen et al. MAGE, BAGE and GAGE gene expression in human rhabdomyosarcomas Int J Cancer 93 2001 85-90
215. P. Daftarian G.Y. Song S. Ali M. Faynsod J. Longmate D.J. Diamond et al. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumours Cancer Res 64 2004 5407-5414
216. J. Espenschied J. Lamont J. Longmate S. Pendas Z. Wang D.J. Diamond et al. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumour model J Immunol 170 2003 3401-3407
217. S. Kusmartsev F. Cheng B. Yu Y. Nefedova E. Sotomayor R. Lush et al. All-trans-retinoic acid eliminates immature myeloid cells from tumour-bearing mice and improves the effect of vaccination Cancer Res 63 2003 4441-4449
218. P.B. Chapman D. Morrisey K.S. Panageas L. Williams J.J. Lewis R.J. Israel et al. Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: A trial comparing doses of G(D2)-keyhole limpet hemocyanin Clin Cancer Res 6 2000 4658-4662
219. D.M. Mahvi F.S. Shi N.S. Yang S. Weber J. Hank M. Albertini et al. Immunization by particle-mediated transfer of the granulocyte-macrophage colony-stimulating factor gene into autologous tumour cells in melanoma or sarcoma patients: Report of a phase I/IB study Hum Gene Ther 13 2002 1711-1721
220. R.O. Dillman M. Wiemann S.K. Nayak C. DeLeon K. Hood C. DePriest Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumour cells from short-term cell line cultures: A randomized phase 2 trial of the cancer biotherapy research group J Immunother 26 2003 367-373
221. R. Dillman N. Barth S. Selvan L. Beutel C. de Leon C. DePriest et al. Phase I/II trial of autologous tumour cell line-derived vaccines for recurrent or metastatic sarcomas Cancer Biother Radiopharm 19 2004 581-588
222. A. Matsuzaki A. Suminoe H. Hattori T. Hoshina T. Hara Immunotherapy with autologous dendritic cells and tumour-specific synthetic peptides for synovial sarcoma J Pediatr Hematol Oncol 24 2002 220-223
223. R. Dagher L.M. Long E.J. Read S.F. Leitman C.S. Carter M. Tsokos et al. Pilot trial of tumour-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: An inter-institute NIH study Med Pediatr Oncol 38 2002 158-164
224. S. Kawaguchi T. Wada K. Ida Y. Sato S. Nagoya T. Tsukahara et al. Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma J Transl Med 3 2005 1
225. A. Takahashi F. Higashino M. Aoyagi K. Yoshida M. Itoh S. et al. Kyo EWS/ ETS fusions activate telomerase in Ewing's tumours Cancer Res 63 2003 8338-8344
226. M. Fanucchi Update on the management of connective tissue malignancies Semin Oncol 31 2004 16-19
227. J. Weitz C.R. Antonescu M.F. Brennan Localized extremity soft tissue sarcoma: Improved knowledge with unchanged survival over time J Clin Oncol 21 2003 2719-2725
228. S. Mocellin M. Provenzano C.R. Rossi P. Pilati D. Nitti M. Lise DNA array-based gene profiling: From surgical specimen to the molecular portrait of cancer Ann Surg 241 2005 16-26
229. S. Mocellin C. Riccardo Rossi P. Traldi D. Nitti M. Lise Molecular oncology in the post-genomic era: The challenge of proteomics Trends Mol Med 10 2004 24-32
230. F.C. Eilber F.R. Eilber J. Eckardt G. Rosen E. Riedel R.G. Maki et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma Ann Surg 240 2004 686-695
231. A. Stojadinovic D.H. Leung P. Allen J.J. Lewis D.P. Jaques M.F. Brennan Primary adult soft tissue sarcoma: Time-dependent influence of prognostic variables J Clin Oncol 20 2002 4344-4352
232. T.O. Nielsen R.B. West S.C. Linn O. Alter M.A. Knowling J.X. O'Connell et al. Molecular characterisation of soft tissue tumours: A gene expression study Lancet 359 2002 1301-1307
233. Y.F. Lee M. John A. Falconer S. Edwards J. Clark P. Flohr et al. A gene expression signature associated with metastatic outcome in human leiomyosarcomas Cancer Res 64 2004 7201-7204
234. A.M. Oliveira C.D. Fletcher Molecular prognostication for soft tissue sarcomas: Are we ready yet? J Clin Oncol 22 2004 4031-4034